Zacks Investment Research upgraded shares of Actelion Ltd. (OTCMKTS:ALIOF) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.

According to Zacks, “Actelion Limited is an independent, profitable, biopharmaceutical company discovering, developing and marketing drugs for high unmet medical needs. “

Actelion (OTCMKTS:ALIOF) opened at 207.20 on Tuesday. The company’s 50-day moving average is $153.24 and its 200 day moving average is $163.76. Actelion has a 1-year low of $124.88 and a 1-year high of $191.34. The firm has a market capitalization of $21.48 billion, a PE ratio of 33.41 and a beta of 1.30.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/30/actelion-ltd-aliof-upgraded-to-hold-by-zacks-investment-research.html.

About Actelion

Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Receive News & Stock Ratings for Actelion Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion Ltd. and related stocks with our FREE daily email newsletter.